Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.
Organisms belonging to the Streptococcus milleri group (SMG) are known for their role in pyogenic infections but have recently been implicated as etiological agents of pulmonary exacerbation in adult patients with cystic fibrosis (CF). The prolonged exposure of CF patients to antibiotics prompted us to investigate the susceptibility profiles of 118 SMG isolates from the airways of CF patients to 12 antibiotics compared to 43 SMG isolates from patients with invasive infections. We found that approximately 60% of all isolates failed to grow using the standard medium for disc diffusion, Mueller-Hinton blood agar (MHBA), so we explored the usefulness of brain heart infusion (BHI) agar for susceptibility testing. Zone-of-inhibition comparisons between BHI and MHBA showed strong correlations for six antibiotics, and interpretations were similar for both medium types. For ceftriaxone and cefepime, both groups of isolates were highly susceptible. Tetracycline resistance levels were comparable between the two groups (22% in CF isolates and 17.4% in invasive isolates). However, more than half of the CF isolates were not susceptible to azithromycin, erythromycin, and clindamycin, compared to 11%, 13%, and 6.5% of invasive isolates, respectively. There were 5-fold and 8-fold increased risks of azithromycin and clindamycin resistance, respectively, for the isolates from the airways of CF patients relative to the invasive isolates. Macrolide resistance was strongly linked to chronic azithromycin therapy in CF patients. This study shows that BHI agar is a suitable alternative for antimicrobial susceptibility testing for the SMG and that SMG isolates from the airways of CF patients are more resistant to macrolides and clindamycin than strains isolated from patients with invasive infections.
Grinwis
Margot E
ME
Department of Microbiology and Infectious Diseases, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada.
Sibley
Christopher D
CD
Parkins
Michael D
MD
Eshaghurshan
Christina S
CS
Rabin
Harvey R
HR
Surette
Michael G
MG
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D017963:Azithromycin / Q000494:pharmacology / Q000627:therapeutic use; D002981:Clindamycin / Q000494:pharmacology / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000382:microbiology*; D024901:Drug Resistance, Multiple, Bacterial; D004917:Erythromycin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D018942:Macrolides / Q000494:pharmacology / Q000627:therapeutic use*; D034364:Streptococcus milleri Group / Q000187:drug effects*; D013752:Tetracycline / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D018942:Macrolides; D002981:Clindamycin; D004917:Erythromycin; D017963:Azithromycin; D013752:Tetracycline
J Infect Chemother. 2002 Jun;8(2):134-7
12111565
Clin Microbiol Infect. 2006 Mar;12(3):224-30
16451408
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15070-5
18812504
J Infect Dis. 1979 Sep;140(3):316-21
501146
Pediatr Pulmonol. 2008 May;43(5):490-7
18383109
Antimicrob Agents Chemother. 2001 May;45(5):1511-4
11302819
Pediatr Infect Dis J. 2007 Jan;26(1):8-12
17195698
J Med Microbiol. 2009 Feb;58(Pt 2):222-227
19141740
J Pediatr. 2002 Mar;140(3):299-305
11953726
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20529-33
18077362
Diagn Microbiol Infect Dis. 1994 Jun;19(2):69-73
7805358
Am J Med. 2006 Oct;119(10):877-83
17000220
Eye (Lond). 2000 Oct;14 Pt 5:814-5
11116727
JAMA. 2003 Oct 1;290(13):1749-56
14519709
J Antimicrob Chemother. 1987 Jun;19(6):831-8
3301785
Curr Opin Investig Drugs. 2009 Aug;10(8):787-94
19649923
Lancet. 2002 Sep 28;360(9338):978-84
12383667
Ann Trop Paediatr. 2006 Dec;26(4):285-91
17132293
Eur J Clin Microbiol Infect Dis. 1999 Jun;18(6):440-4
10442424
Am J Respir Crit Care Med. 2007 Nov 15;176(10):957-69
17761616
Br Med J. 1977 Oct 15;2(6093):981-4
336141
Antimicrob Agents Chemother. 1995 Oct;39(10):2243-7
8619576
Br Med J (Clin Res Ed). 1981 Sep 26;283(6295):819-21
6794712
Clin Microbiol Rev. 1988 Jan;1(1):102-8
3060239
Am Surg. 2007 May;73(5):492-7
17521006
Thorax. 2000 Mar;55(3):251-2
10744544
Eur Respir J. 1998 Aug;12(2):357-62
9727785
J Med Microbiol. 2010 May;59(Pt 5):534-540
20093379
J Antimicrob Chemother. 2006 Apr;57(4):741-6
16469851
J Antimicrob Chemother. 2009 Sep;64(3):501-6
19584106
Eur J Clin Microbiol Infect Dis. 2007 Jan;26(1):1-11
17180609
Eur J Clin Microbiol Infect Dis. 1998 Aug;17(8):556-60
9796653
Thorax. 1995 Oct;50(10):1093-6
7491559
Chest. 1998 Dec;114(6):1588-93
9872193
J Cyst Fibros. 2009 Jan;8(1):58-62
18849202
Arch Dis Child. 1999 Mar;80(3):278-9
10325713
Antimicrob Agents Chemother. 2001 Aug;45(8):2375-7
11451701
Antimicrob Agents Chemother. 1995 Mar;39(3):577-85
7793855
Clin Infect Dis. 1995 Dec;21 Suppl 3:S238-43
8749672
Antimicrob Agents Chemother. 1996 Apr;40(4):891-4
8849246
N Engl J Med. 1993 Jun 17;328(24):1740-6
8497284
Pediatr Infect Dis J. 2002 Aug;21(8):715-23
12192158
J Clin Microbiol. 1996 Aug;34(8):2020-2
8818904
Thorax. 2002 Mar;57(3):212-6
11867823
Jpn J Infect Dis. 2008 Nov;61(6):484-6
19050362
J Clin Microbiol. 2010 Feb;48(2):395-401
20007382
J Antimicrob Chemother. 1999 Mar;43(3):399-402
10223596
Antimicrob Agents Chemother. 1991 Jul;35(7):1267-72
1929280